Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation

Chapman, J. D.; Schneider, Richard F.; Urbain, Jean-Luc; Hanks, Gerald E.

doi:10.1053/srao.2001.18103

Cited by 57 publications

(27 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With positron emission tomography (PET), radiolabeled hypoxia-avid compounds can be applied to evaluate oxygenation status in experimental or human tumors [3]. Nitroimidazoles are recognized to selectively bind to hypoxic cells [16] and are reduced intracellularly.…”

Section: Introductionmentioning

confidence: 99%

pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose)

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose)

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The latter, 124 Iazomycin-galactoside, has been studied by microPET in rodent models (43). The properties of these compounds have been compared with other 2-nitroimidazoles (e.g., [ 18 F]FMISO) and reviewed by Chapman et al (44). Differences between the tracers include the lipid/water partition coefficients, the hypoxia-specific factor, and the pO 2 dependency (or the k-curve) of binding.…”

Section: Different Technologies For Identifying and Measuringtissue Hmentioning

confidence: 99%

Tumor Hypoxia Imaging

Serganova

Humm

Ling

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

In this issue of Clinical Cancer Research, Rajendran et al. (1) have assessed the value of pretherapy fluoromisonidazole (FMISO) positron emission tomography (PET) imaging, an indicator of tissue hypoxia, in predicting survival of 73 patients with head and neck cancers. In this study, the FMISO imaging results were not used to guide therapeutic management and, thus, had no influence on the survival results. The images of 58 (79%) patients indicated significant hypoxia based on a PET image intensity threshold criterion established by the experienced University of Washington group. A univariate analysis showed a significant correlation between survival and two measured variables: the maximum tumor/blood ratio (T/B max ) at 4.5 hours after FMISO administration (P = 0.002) and the hypoxic tumor volume (P = 0.04). The presence of node metastases was also correlated with survival (P = 0.01). A similar univariate analysis of a subset of 52 patients who had a 2 ¶-fluoro-2 ¶-deoxyglucose (FDG) PET scan did not yield a correlation between FDG standardized uptake value and survival (P = 0.14).This result is surprising because in an earlier publication, Rajendren et al. (2) showed good voxel-by-voxel correlation between FDG and FMISO uptake in head and neck cancer (0.62), but not in breast cancer (0.47), glioblastoma multiforme (0.38), or soft tissue sarcoma (0.32). Interestingly, the investigators report that no variable was predictive of survival in a multivariate analysis that included the FDG maximum standard uptake value, whereas both nodal status and T/B max (or HV) were highly predictive when the FDG maximum standard uptake value was removed from the model. Could the biology behind these observations shed some light on these results?

show abstract

“…Several other compounds, labeled with various radioactive isotopes, can be used to mark hypoxic cells for later view with PET or SPECT (single photon emission computed tomography) (Chapman et al, 1998). Such techniques, along with MRI (magnetic resonance imaging), may provide an important step towards individualized radiation therapy (Rasey et al, 1996;Cooper et al, 2000;Chapman et al, 2001;Krishna et al, 2001;Mankoff and Bellon, 2001).…”

Section: The Radiation Response Of Hypoxic Cells and Tumorsmentioning

confidence: 99%

Accurate description of heterogeneous tumors for biologically optimized radiation therapy

Nilsson

2005

Medical Physics

View full text Add to dashboard Cite

In this thesis, a model of tissue oxygenation is presented, that takes into account the heterogeneous nature of tumor vasculature. Even though the model is rather simple, the resulting oxygen distributions agree very well with clinically observed oxygen distributions for most tumors and healthy normal tissues. The model shows that the vascular density may not describe the oxygenation of a tissue sufficiently well, unless the heterogeneity of the vascular system is taken into account. Based on the oxygen distributions from the tissue model, the associated radiation response at low and high doses can be determined.The radiation response of heterogeneous tumors should preferably be described by two clonogen compartments, one resistant and one sensitive, dominating the response at high and low radiation doses, respectively. Furthermore, each compartment should be characterized by the effective radiation resistance and the effective clonogen number. The resistant-sensitive model of radiation response has been analyzed in great detail. It accurately describes the response of severely heterogeneous tumors, both at low and high doses and LET values. The effective response parameters are given as integrals, averaged over the whole spectrum of radiation resistance. The parameters can also be determined from clinically established dose-response relations.The main properties of the dose-response relation for a generally heterogeneous tumor is described in some detail. The normalized dose-response gradient has been generalized to take heterogeneities in both dose delivery and radiation response into account. This quantity is important for accurate treatment plan optimization using intensity modulated radiation therapy for individual patients.

show abstract

Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation

Cited by 57 publications

References 41 publications

pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose)

pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose)

Tumor Hypoxia Imaging

Accurate description of heterogeneous tumors for biologically optimized radiation therapy

Contact Info

Product

Resources

About